NYC Research Inc — research payments reported

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$975,820	24
2024	Research	$898,703	27
2023	Research	$671,871	200
2022	Research	$388,391	124
2021	Research	$166,249	194
2020	Research	$105,138	138
2019	Research	$163,565	94

Breakdown

Who paid Research payments · program years 2019–2025

Eli Lilly and Company $2,478,829 38 payments
Novo Nordisk AS $438,118 727 payments
AbbVie, Inc. $330,118 22 payments
Mannkind Corporation $110,472 13 payments
AstraZeneca Pharmaceuticals LP $12,200 1 payment

Studies the money was for Research payments · program years 2019–2025

A Phase 3 Randomized Double Blind Study to Investigate the Efficacy and Safety of Once Daily Oral Ly3502970 Compared With Placebo in Adult Participants With Obesity Or Overweight and Type 2 Diabetes (Attain-2) $572,447 4 payments
A Phase 3, Multicenter, Randomized, Parallel-Design, Open-Label Trial to Evaluate the Efficacy and Safety of Ly3209590 Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin (Qwint-3) $357,544 5 payments
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Safety of Tirzepatide Once Weekly Compared to Placebo in Adult Participants With Type 1 Diabetes and Obesity Or Overweight (Surpass-T1d-1) $270,306 1 payment
Nn9535-4352 $261,702 669 payments
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants $258,238 16 payments
A Phase 3, Randomized, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly Compared With Semaglutide Once Weekly in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With Or Without Sglt2 Inhibitor (Transcend-T2d-2) $244,580 4 payments
A Phase 3 Multicenter Randomized Parallel-Design Open-Label Study to Evaluate the Efficacy and Safety of Ly3209590 As A Weekly Basal Insulin Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy $210,739 2 payments
A Phase 3 Multicenter Randomized Parallel-Design Open-Label Trial to Evaluate the Efficacy and Safety of Ly3209590 Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin (Qwint-3) $202,876 2 payments
Nn9536-4376 $140,971 36 payments
A Phase 3, Randomized, Multicenter, Double-Blind Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly Compared With Placebo in Adult Participants With Type 2 Diabetes, Moderate Or Severe Renal Impairment With Inadequate Glycemic Control on Basal Insulin With Or Without Metformin And/Or Sglt2 Inhibitor $128,356 4 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.